RadNet (RDNT) Earns News Sentiment Rating of 0.16

Media headlines about RadNet (NASDAQ:RDNT) have trended somewhat positive on Tuesday, according to Accern. The research group rates the sentiment of media coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. RadNet earned a daily sentiment score of 0.16 on Accern’s scale. Accern also assigned news stories about the medical research company an impact score of 46.3054176993278 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.

These are some of the media headlines that may have impacted Accern Sentiment Analysis’s scoring:

Shares of RadNet traded down $0.20, hitting $12.95, during mid-day trading on Tuesday, according to Marketbeat Ratings. 2,102 shares of the company were exchanged, compared to its average volume of 417,716. The company has a debt-to-equity ratio of 4.90, a current ratio of 1.12 and a quick ratio of 1.12. RadNet has a 1-year low of $7.01 and a 1-year high of $14.85. The company has a market cap of $627.11 million, a PE ratio of 44.66, a P/E/G ratio of 4.45 and a beta of 0.42.



RadNet (NASDAQ:RDNT) last issued its quarterly earnings results on Wednesday, May 9th. The medical research company reported ($0.15) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.04 by ($0.19). RadNet had a positive return on equity of 18.77% and a negative net margin of 0.66%. The company had revenue of $231.39 million for the quarter, compared to analyst estimates of $234.32 million. During the same period in the prior year, the business earned ($0.03) earnings per share. RadNet’s revenue for the quarter was up 1.0% compared to the same quarter last year. analysts anticipate that RadNet will post 0.37 earnings per share for the current fiscal year.

Several equities research analysts have recently weighed in on the company. FIX assumed coverage on RadNet in a report on Wednesday, March 14th. They issued a “strong-buy” rating and a $15.00 price objective for the company. Zacks Investment Research downgraded RadNet from a “hold” rating to a “sell” rating in a report on Saturday, February 24th. Jefferies Group set a $14.00 price target on RadNet and gave the stock a “buy” rating in a report on Thursday, March 8th. ValuEngine raised RadNet from a “hold” rating to a “buy” rating in a report on Wednesday, May 2nd. Finally, BidaskClub raised RadNet from a “hold” rating to a “buy” rating in a report on Wednesday, March 14th. One investment analyst has rated the stock with a hold rating, three have issued a buy rating and two have assigned a strong buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus target price of $14.75.

In related news, insider Jeffrey L. Linden sold 10,000 shares of the stock in a transaction on Wednesday, March 14th. The stock was sold at an average price of $13.09, for a total transaction of $130,900.00. Following the completion of the sale, the insider now directly owns 922,001 shares of the company’s stock, valued at $12,068,993.09. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, VP Mark Stolper sold 15,000 shares of the stock in a transaction on Tuesday, March 20th. The stock was sold at an average price of $13.19, for a total value of $197,850.00. Following the sale, the vice president now directly owns 130,319 shares of the company’s stock, valued at $1,718,907.61. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 138,927 shares of company stock valued at $1,796,452. Corporate insiders own 7.56% of the company’s stock.

About RadNet

RadNet, Inc, together with its subsidiaries, provides outpatient diagnostic imaging services in the United States. Its services include magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other related procedures, as well as multi-modality imaging services.

Insider Buying and Selling by Quarter for RadNet (NASDAQ:RDNT)

Receive News & Ratings for RadNet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RadNet and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply